Another direction for an immune‐modulatory treatment approach might emerge by interfering with the CSF‐1‐CSF‐1R axis, based on the robust and persistent amelioration of neuropathy by CSF‐1 deficiency in different CMT1 mouse models (Carenini et al., 2001; Groh et al., 2012). The gene discussed is MPZ; the disease is neuropathy.